Armis Biopharma today said it received FDA approval for its VeriFixx Small Bone Implant.
The implant is designed for the fixation of osteotomies and reconstruction of the lesser toes following correction procedures for hammertoe, claw toe and mallet toe. VeriFixx can also make surgical corrections more accessible to patients in a shorter time to ambulation with a shorter overall recovery time and reduced pain, according to the company.
“For patients requiring a small bone implant, the length of recovery and pain are common concerns,” CEO Ted Ziemann said in a news release. “With our unique proprietary design, we are excited to bring a new technology to the medical device market that specifically addresses these concerns while maintaining the benefits of current standard of care.”
VeriFixx features a unique alignment fin design and a sub-micron layer of commercially pure titanium that is molecularly bonded to a PEEK implant using atomic fusion deposition. The implant is designed to provide ideal fixation alignment and a bone-friendly titanium surface.
